Malaysia's deputy foreign minister Kamarudin Jaffar said India has agreed to sell hydroxychloroquine to Malaysia for use to treat COVID-19 patients, as reported in NASDAQ.
Last month, the Indian government had put a hold on exports of hydroxychloroquine to secure supplies for itself, before agreeing this month to supply it to some of its neighbours as well as "nations who have been particularly badly affected by the pandemic."
Jaffar stated that "on April 14, India has given permission for Malaysia to import 89,100 tablets," adding "we will try to get more hydroxychloroquine tablets from India, which is also subject to stock availability."
The news source said Malaysia has been using hydroxychloroquine for mild-to-severe COVID-19 cases along with other drugs, according to its treatment protocol.
Teva, Ipca Laboratories and Cadila Healthcare are among India's leading suppliers of hydroxychloroquine, the news source added.
Cadila said last week that it had increased production ten-fold to 30 tonnes per month and was ready to produce more if needed.
To read more NewsPoints articles, click here.